Physician profile
Daniel E Mcguire
NPI 1205869526
$9,387.19
in general payments reported to CMS, 2019-2025
42 companies · $1,893 in 2025
The $1,893 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,015 · 2020: $391 · 2021: $1,449 · 2022: $1,714 · 2023: $1,346 · 2024: $1,580 · 2025: $1,893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,719 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,719.12 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,035.21 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $608.64 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Janssen Biotech, INC. | $536.33 | 2019-2025 | Stelara, Tremfya, Simponi |
| Gilead Sciences, INC. | $496.41 | 2019-2025 | |
| Celgene Corporation | $463.08 | 2021-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $319.72 | 2019-2023 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $318.53 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Merck Sharp & Dohme LLC | $314.60 | 2019-2024 | Dificid |
| Phathom Pharmaceuticals, INC. | $310.91 | 2024-2025 | Voquezna |
| Genzyme Corporation | $300.21 | 2022-2025 | |
| Pfizer INC. | $274.13 | 2021-2025 | |
| Ipsen Biopharmaceuticals, INC | $259.48 | 2025 | Iqirvo |
| Qol Medical, LLC | $248.13 | 2019-2025 | Sucraid, Sucraid |
| E.R. Squibb & Sons, L.L.C. | $228.19 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $212.29 | 2021-2023 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $209.37 | 2019-2023 | Sutab |
| Vivus LLC | $183.50 | 2020-2025 | Pancreaze, Qsymia |
| Lilly USA, LLC | $119.18 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $88.20 | 2025 | Rezdiffra |
| Ferring Pharmaceuticals INC. | $82.79 | 2019-2023 | Rebyota |
| Ucb, INC. | $71.02 | 2019-2021 | |
| Allergan, INC. | $60.15 | 2019 | |
| Aimmune Therapeutics, INC. | $59.55 | 2024-2025 | Zenpep |
| Ironwood Pharmaceuticals, INC | $58.94 | 2022-2023 | Linzess |
| Novo Nordisk INC | $43.05 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $40.57 | 2019 | |
| Celltrion USA INC. | $40.56 | 2024 | Vegzelma |
| Evoke Pharma, INC. | $39.63 | 2023-2025 | Gimoti |
| Medtronic, INC. | $39.56 | 2022 | |
| Romark Laboratories, Lc | $38.90 | 2019 | |
| Zimmer Biomet Holdings, INC. | $36.27 | 2024 | Persona |
| Redhill Biopharma INC. | $30.61 | 2023 | Talicia |
| Fresenius Kabi USA, LLC | $30.21 | 2024 | Idacio |
| Organon LLC | $28.16 | 2021 | |
| Ardelyx, INC. | $27.25 | 2025 | Ibsrela |
| Csl Behring | $24.29 | 2022 | |
| Biocon Biologics INC | $23.78 | 2024 | Hulio |
| Amgen INC. | $21.10 | 2022 | |
| Concordia Pharmaceuticals INC. | $19.89 | 2019 | |
| Boston Scientific Corporation | $19.08 | 2023 | Watchman Flx |
| Regeneron Healthcare Solutions, INC. | $17.47 | 2022 | |
| Micro-Tech Endoscopy USA, INC. | $8.25 | 2024 | Cold Snares |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mcguire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.